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Abstract. Despite the implementation of effective conjugate vaccines against the threemain bacterial pathogens that
causemeningitis,Streptococcuspneumoniae,Haemophilus influenzae typeb (Hib), andNeisseriameningitidis serogroup
A, the burden of meningitis in West Africa remains high. The relative importance of other bacterial, viral, and parasitic
pathogens in central nervous system infections is poorly characterized. Cerebrospinal fluid (CSF) specimens were
collected from children younger than 5 years with suspectedmeningitis presenting at pediatric teaching hospitals across
West Africa in five countries including Senegal, Ghana, Togo, Nigeria, and Niger. Cerebrospinal fluid specimens were
initially tested using bacteriologic culture and a triplex real-time polymerase chain reaction (PCR) assay for
N.meningitidis,S. pneumoniae, andH. influenzae for routinemeningitis surveillance.A custom TaqMan Array Card (TAC)
assay was later used to detect 35 pathogens including 15 bacteria, 17 viruses, one fungus, and two protozoans. Among
711CSFspecimens tested, thepathogenpositivity rateswere2%and20%by the triplex real-timePCR (threepathogens)
and TAC (35 pathogens), respectively. TAC detected 10 bacterial pathogens, eight viral pathogens, and Plasmodium.
Overall, Escherichia coli was the most prevalent (4.8%), followed by S. pneumoniae (3.5%) and Plasmodium (3.5%).
Multiple pathogensweredetected in 4.4%of the specimens.ChildrenwithHIV andPlasmodiumdetected inCSFhadhigh
mortality. Among 220 neonates, 17% had at least one pathogen detected, dominated by Gram-negative bacteria. The
meningitis TAC enhanced the detection of pathogens in children with meningitis and may be useful for case-based
meningitis surveillance.
INTRODUCTION
Meningitis is a life-threatening inflammatory disease of the
brain and spinal cord that can be caused by bacterial, viral,
fungal, and parasitic infections.1 The greatest burden occurs
in sub-Saharan Africa, bearing half of the estimated 2.8million
cases and58%of the 318,400deaths estimated annually.2Up
to a quarter of bacterial meningitis survivors may be left with
sequelae including cognitive impairment, paralysis, and
hearing loss.3 Children younger than 5 years are dispropor-
tionately affected.2
Before the rollout of effective conjugate vaccines,Neisseria
meningitidis, Haemophilus influenzae type B (Hib), and
Streptococcus pneumoniae accounted for the bulk of men-
ingitis cases in children.2,4,5 However, as vaccines for these
three bacterial pathogens have been introduced across West
Africa, the relative importance of other causes of meningitis
such as Gram-negative bacteria, ß-hemolytic streptococci,
Staphylococcus, Listeria, fungi, and viruses has increased.2
The broad spectrum of meningeal pathogens, some of which
require special therapy or should not receive antibiotics,
poses new challenges for rapid and accurate diagnosis.
Historically, meningitis diagnosis and surveillance are
hindered by the very low pathogen yields from bacteriologic
culture. Mwenda and colleagues reported that culture
confirmation was less than 1% among 48,284 children
younger than 5 years with suspected meningitis across
26 African countries.6 Accordingly, the WHO has recom-
mended improved diagnostics and surveillance as key pri-
orities on their road map to eliminate epidemic meningitis in
Africa by 2030.7 A technical task force identified the need for
a multiplex diagnostic tool with the capacity to simulta-
neously detect meningeal pathogens. Real-time polymer-
ase chain reaction (PCR)–based tools have the capacity to
detect meningeal pathogens with high sensitivity, specificity,
and reproducibility.8–10 Several meningitis/encephalitis mo-
lecular multiplex PCR assays have been developed, some of
which are commercially available.
In this work, because of the ability to customize the path-
ogens we wished to detect, we used the TaqMan Array Card
(TAC). TaqMan Array Cardis a compartmentalized probe-
based real-time PCR system that uses microfluidic technol-
ogy, with PCRs configured in a 384-well array format. TaqMan
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Array Card can be used to simultaneously and accurately
detect bacterial, viral, protozoan, and fungal pathogens using
very small volumes of the clinical specimen. TAC has been
used to improve the diagnostic yield in other low-resource
settings, for example, determining the etiologyof febrile illness
and sepsis in East Africa11,12 and South Africa.13 Saha and
colleagues used the TAC platform to determine the etiology of
community-acquired neonatal infections in South Asia.14 We
have previously used the TAC platform to improve the case-
level and population-level ascertainment of the causes of
diarrhea in multiple countries.15
We therefore used a customized TAC assay that targets 35
meningitis andencephalitis pathogens for case ascertainment
in cerebrospinal fluid (CSF) specimens collected from five
West African countries among children younger than 5 years
with suspected meningitis. Our study included suspected
meningitis cases that occurred between 2017 and 2018, after
the rollout of the pneumococcal conjugate vaccine (PCV), the
meningococcal A protein–polysaccharide conjugate vaccine
(MenAfriVac), and the Hib conjugate vaccine in all five coun-
tries. This study therefore allowed an examination of the
meningitis pathogens that countries should prioritize.
METHODS
Surveillance design and sample collection. The WHO
CollaboratingCenter for NewVaccinesSurveillance (WHOCC
NVS) hosted at the Medical Research Council Unit, the
Gambia, at the London School of Hygiene and Tropical
Medicine (MRCGat LSHTM) also serves as theWHORegional
Reference laboratory (WHO RRL) for invasive bacterial dis-
eases. The WHO CC and RRL support the WHO-coordinated
Pediatric Bacterial Meningitis Surveillance (PBM) network
across 10 countries inWest and Central Africa, a region of the
world with high under-five mortality. The WHO-coordinated
PBM enrolled children younger than 5 years with suspected
meningitis presenting at sentinel sites. The sentinel sites
participating in the PBM network are pediatric teaching and
referral hospitals. The six sentinel sites included in this study
were in Senegal (Dakar),16 Ghana (Kumasi and Accra),17 Togo
(Lome),18 Nigeria (Enugu),19 and Niger (Niamey),20 all coun-
tries at risk of meningitis epidemics.21 The sentinel sites in
Niger and Senegal fall within the hyperendemic region of the
meningitis belt. The sentinel sites were selected for the TAC
study based on the quality of the surveillance data and the
number of samples available for TAC testing.6
Suspected cases were any child aged 0–59 months ad-
mitted to a sentinel hospital conducting surveillance with a
sudden onset of fever (> 38.5C rectal or 38.0C axillary) and
one of the following signs: neck stiffness, altered conscious-
ness (with no other alternative diagnosis), or other meningeal
signs.22,23 Lumbar puncture was performed to obtain CSF
from suspected cases. Standard bacteriology, cytology and
biochemistry were performed on CSF specimens at the sen-
tinel sites.24 The remaining CSF specimens were stored
at −20C until they were shipped on dry ice to the WHO RRL
and stored at −80C until testing. For this pilot, we tested all
residual CSF with volumes of at least 150 μL collected be-
tween January 2017 and June 2018 from the sentinel sites.
Ethics review and approvals. The standard operating
procedures and protocols for this pilot were approved by
The joint Gambia Government/MRCG at LSHTM Ethics
Committee. The TAC diagnostics were provided by the Uni-
versity of Virginia, VA, whose IRB approved the grant pro-
posal. Approval was granted by the Ministries of Health of the
participating countries to test CSF samples collected as part
of ongoing routine surveillance for vaccine-preventable
diseases.
Laboratoryprocedures.Triplex real-timePCRdetectionof
N. meningitidis, S. pneumoniae, and H. influenzae was per-
formed at the WHO CC NVS as described previously.25,26 For
this pilot, we assessed etiologies using a custom-made TAC
(Thermo Fisher Scientific, CA) that compartmentalized probe-
based qPCR assays for 35 pathogens selected based on
the global, regional, and national estimates of meningitis
and sepsis.2,27 The TAC assay included 15 bacteria (Barto-
nella spp.; Brucella spp.; Escherichia coli/Shigella spp.;
H. influenzae, Hib; Klebsiella pneumoniae; Leptospira spp.;
Listeria monocytogenes; Mycoplasma pneumoniae; Myco-
bacterium tuberculosis; N. meningitidis; N. meningitidis
serogroups A, B, C, W, X, and Y; Rickettsia spp.; Salmonella
enterica; Staphylococcus aureus; Streptococcus agalactiae;
andS. pneumoniae), 17 viruses (adenovirus, cytomegalovirus,
dengue, Epstein–Barr virus, enterovirus, humanherpesvirus6,
herpes simplex virus 1, herpes simplex virus 2, HIV I, HIV II,
influenza A, measles, mumps, parechovirus, parvovirus B19,
varicella zoster virus, and West Nile virus), one fungus (Cryp-
tococcus neoformans), and two protozoans (Plasmodium
spp.,Plasmodium falciparum, andToxoplasmagondii). Primer
and probe sequences were adapted largely from Onyango
and colleagues28 as well as from our prior work and other
publications using the same platform.11,29–31 New assays
developed and validated for this project are listed in
Supplemental File 1. For each specimen, at least 150μLbut up
to 200 μL of the CSF underwent nucleic acid extraction using
QIAamp MinElute Virus Spin kit (Qiagen, Hilden, Germany)
following the manufacturer’s instruction. Samples with less
than 150 μL of the CSF were excluded. When the sample
volume was less than 200 μL, 0.9% sodium chloride was
supplemented to bring the volume to 200 μL. This affected
< 3% of specimens tested. Two external controls, bacterio-
phage MS2 and phocine herpesvirus, were added to assess
extraction and amplification efficiency. We included one ex-
traction blank per batch of extraction to monitor contamina-
tion. Purified nucleic acids were subjected to TAC qPCR. The
reaction mixes contained 25 μL of TaqMan Fast Virus 1-Step
MasterMix and 75 μL of total nucleic acid extract or nuclease-
free water as negative control. We included one negative
control per 10 cards to exclude laboratory contamination.
Amplification involved a reverse transcription step at 50C for
10minutes, and then an initial denaturation step at 95C for 20
seconds, followed by 40 cycles of 95C for 3 seconds and
60C for 30 seconds. All detections with a cycle quantification
(Cq) value greater than 35 were considered negative. Valid
results required proper functioning of controls and excluded
data flagged by the QuantStudio™ seven Flex software
(Thermo Fisher Scientific version 1.2), and 99% of specimens
had valid results. The WHO RRL participates in the WHO Ex-
ternal Quality assessment program for the invasive bacterial
vaccine preventable diseases, UK NEQAS for Microbiology
(http://www.ukneqasmicro.org.uk).
Statistical analysis. Participant characteristics were sum-
marized using proportions for categorical variables and me-
dians for continuous variables. We examined associations
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using chi-square/Fisher’s exact and Mann–Whitney U test for
categorical and continuous variables, respectively. Odds ra-
tios were calculated to assess the pathogen association with
mortality where possible. Accuracy was determined with ref-
erence to the triplex real-time PCR results. All tests were two-
tailed, at 5% significance level. Analyses were performed
using SPSS (version 25.0; IBM Corp, Armonk, NY) and Stata
statistical software: Release 12 (StataCorp LP, TX).
RESULTS
During the study period, a total of 1,535 suspected menin-
gitis cases were reported across the sentinel sites, and 1,088
CSF specimens were sent to the WHO RRL for molecular
testing. Reasons for CSF samples not being sent to the WHO
RRL vary but include 1) lumbar puncture not performed, 2)
insufficient volumes of CSF, and 3) missing CSF samples. Of
the CSF samples received at the RRL, 717/1088 (65%) had
sufficient volume to perform TAC analysis, and, of these, 711/
717 (99%) yielded valid TAC results. The characteristics of
patients with valid TAC results are shown in Table 1. The
surveillance site in Ghana enrolled predominantly neonates
(median age, <1month),whereas in theother sites, toddlers or
young children accounted for the bulk of suspected cases
(median ages at other sites, 11–36 months). A majority (67%)
of children in Ghana reported having received antibiotics be-
fore lumbar puncture, whereas prior antibiotic treatment
was less commonly reported at the other sites (0–35%).
The CSF samples were collected on average 3 days after
the onset of the illness. Most children did not have
significant CSF pleocytosis (87% had CSF WBC < 10).
Among the 605 patients with outcome at discharge in-
formation, 9.8% died.
Pathogen detection by TAC. Overall, 20% of the samples
had at least one pathogen detected, including 10 bacterial
pathogens, eight viral pathogens, and Plasmodium. The
pathogen detection rate was 22% for Ghana, 24% for Nigeria,
29% forNiger, 45% forSenegal, and8% for Togo.Escherichia
coli was the most prevalent (4.8%, Figure 1), followed by
S. pneumoniae (3.5%) andPlasmodium (3.5%).Onepathogen
was detected in 15.6% of specimens, whereas 4.4% of
specimens contained > 1 pathogen. The period from illness
onset to CSF collection was 3 days (interquartile range: 1–6).
There was no difference in the duration of illness in those with
pathogens detected versus those without (P > 0.05).
Comparison of TAC results with the triplex real-time
PCR results. CSF culture was performed on 707 fresh CSF
samples, for an overall 2.0% pathogen detection rate. Com-
pared with the culture results, TAC detected the only
H. influenzae case, all three S. pneumoniae cases, and one of
the two N. meningitidis cases confirmed by culture (see
Supplemental Table).
In addition, 711 CSF samples were previously tested for
N. meningitidis, H. influenzae, and S. pneumoniae using a tri-
plex real-time PCR assay. The human RNAse P gene internal
control failed in 249 specimens, and these results were cen-
sored according to the protocol. Of the 462 specimens with
conclusive results, there were nine positive results by triplex
real-time PCR. TAC detected 3/3 N. meningitidis, 4/5
S. pneumoniae, and 0/1 H. influenzae results; however, this
TABLE 1
Clinical characteristics of the suspected meningitis cases enrolled in surveillance
Ghana Nigeria Niger Senegal Togo
Suspected meningitis cases reported 351 177 320 146 541
CSF specimens tested by TAC† 205 139 31 31 305
Gender
Male, n (%) 115 (56) 82 (59) 18 (58) 19 (61) 176 (58)
Age (months)‡
Median (months) 0.6 23 36 11 16
< 1, n (%) 123 (60) 10 (7.2) 0 8 (26) 77 (25)
1–23, n (%) 59 (29) 55 (40) 11 (36) 13 (42) 100 (33)
24–59, n (%) 22 (11) 74 (53) 20 (65) 10 (32) 128 (42)
Collection date 01/2017–02/2018 01/2017–06/2018 04/2017–03/2018 01/2017–12/2017 01/2017–02/2018
Median days between onset and CSF
collection (range)
3 (0–26) 5 (0–33) 1 (0–5) 4.5 (0–61) 3 (0–30)
Antibiotic usage, n (%)
Yes 137 (71) 0 0 12 (40) 56 (35)
No 56 (29) 121 (100) 1 18 (60) 104 (65)
CSF white blood count (cells/mm3), n (%)
< 10 179 (90) 139 (10) 23 (74) 8 (27) 270 (89)
10–100 10 (5.0) 0 6 (19) 9 (30) 27 (8.9)
> 100 11 (5.5) 0 2 (6.5) 13 (43) 6 (2.0)
Cerebrospinal fluid glucose (mg/dL),n (%)
< 40 22 (18) 8 (5.8) 6 (40) 11 (37) 24 (9.1)
40–100 101 (80) 126 (91) 9 (60) 19 (63) 191 (72)
> 100 3 (2.4) 5 (3.6) 0 0 50 (19)
Outcome at discharge, n (%)
Died 5 (2.4) 22 (16) 5 (16) 4 (13) 23 (11)
Discharged alive 196 (96) 103 (75) 13 (42) 22 (71) 164 (82)
Transferred 1 (0.5) 0 13 (42) 3 (9.7) 0
Left against medical advice 1 (0.) 12 (8.8) 0 0 14 (7.0)
Pending discharge 2 (1.0) 0 0 2 (6.5) 0
* Although there were a total of 1,535 suspected meningitis cases reported during the study period, lumbar puncture was performed.
†This excludes the six samples that failed in the TAC analysis.
‡Not all the information was available for all the patients. Percentage was calculated for the samples with the corresponding information available.
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latter specimen had a high Cq of 35.8 by triplex real-time
qPCR, indicative of a low H. influenzae bacterial load.
Therefore, TAC yielded an overall sensitivity of 78% (7/9)
and 99% specificity (1,358/1,377) versus triplex real-time
PCR yet detected an additional 17 S. pneumoniae and two
N. meningitidis cases. TAC also detected an additional 22
S. pneumoniae and four N. meningitidis cases compared
with culture. Thus, the overall yield of a potential etiology
FIGURE 1. Overall pathogen detection in different age-groups among West African children younger than 5 years with suspected meningitis.
TABLE 2
Pathogen detection (%) in the five countries
Ghana (n = 205) Nigeria (n = 139) Niger (n = 31) Senegal (n = 31) Togo (n = 305)
Escherichia coli 5 (2.4) 20 (14) – 5 (16) 4 (1.3)
Plasmodium 3 (1.5) 5 (3.6) 2 (6.5) – 15 (4.9)
Streptococcus pneumoniae 13 (6.3) 4 (2.9) 4 (13) 3 (9.7) 1 (0.3)
Staphylococcus aureus 8 (3.9) 2 (1.4) – 3 (9.7) 8 (2.6)
Klebsiella pneumoniae 7 (3.4) 8 (5.7) 2 (6.5) 2 (6.5) –
Parvovirus B19 – 8 (5.7) 1 (3.2) 1 (3.2) 2 (0.7)
Streptococcus agalactiae 6 (2.9) 1 (0.7) – – –
Dengue 3 (1.5) – – 1 (3.2) 2 (0.7)
Neisseria meningitidis 1 (0.5) 1 (0.7) 3 (9.7) – 1 (0.3)
CMV 2 (1.0) – – 1 (3.2) 2 (0.7)
EBV – 2 (1.4) 1 (3.2) – 1 (0.3)
HIV I – 1 (0.7) 1 (3.2) – 2 (0.7)
Enterovirus 3 (1.5) – – – –
HHV 6 2 (1.0) – – – 1 (0.3)
Mumps 1 (0.5) – – – 1 (0.3)
HIV II – – – – 1 (0.3)
Bartonella 1 (0.5) – – – –
Haemophilusinfluenzae – – 1 (3.2) – –
Mycobacterium tuberculosis – 1 (0.7) – – –
Rickettsia – 1 (0.7) – – –
Total pathogen detection rate 45 (22) 33 (24) 9 (29) 14 (45) 24 (8.0)
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was 20% (143/711) by TAC versus 2.0% by culture and
2.4% by triplex real-time PCR.
Pathogen detection by country and by age. Table 2
shows the distribution of pathogens in the five countries.
Bacteria were the dominant pathogens across all the sites,
except Togo, where Plasmodium was the leading pathogen
detected in 5.0% of the specimens. The most common
pathogen was S. pneumoniae in Ghana (6.3%) and Niger
(13%), whereas it was E. coli in Nigeria (14%) and Senegal
(16%). Among 220 neonates (aged 0–28 days), 17% had at
least one pathogen detected, dominated by the Gram-
negative bacterial pathogens (Figure 1). Escherichia coli,
K. pneumoniae, and S. pneumoniae were consistently de-
tected across all age-groups. Plasmodium was exclusively
detected in 1- to 59-month-old children. Similarly, more viru-
ses were detected in older age-groups, in particular parvovi-
rus B19.
Effect of antibiotics usage on pathogen detection. An-
tibiotic usage information was available for 71% of the pa-
tients. Forty-one percent of patients reported antibiotic
treatment before admission, and the reported usage varied
greatly by site. Although overall bacterial pathogen detection
was similar with or without antibiotics, there were consider-
able differences for E. coli and Plasmodium detection, with
lower rates in those that reported having received antibiotics:
3.4% versus 8.0% for E. coli (P = 0.038) and 0.5% versus
3.7% for Plasmodium (P = 0.033).
Other laboratory testing. Probable meningitis was pre-
classified as a suspected meningitis case with turbid appear-
anceorWBC>100cells/mm3or aWBC10–100cells/mm3with
elevated protein (> 100mg/dl) or decreased glucose (< 40mg/
dL).32 Among the 20 CSF samples from these probable men-
ingitis cases, a high rate (55%, 11/20)were positive for bacterial
pathogens, including one E. coli, five K. pneumoniae, one
N. meningitidis, and four S. pneumoniae. In addition, the path-
ogen loads (indicated by the real-time PCR Cq) in these spec-
imens were significantly higher than the quantity in those with
low white blood cell counts and high glucose concentration
(Mann–Whitney U test, P = 0.035). As expected, among sam-
ples with lowwhite blood count (< 10 cells/mm3), the detection
rate was 19% (117/618). We included some N. meningitidis
serogrouping on the TAC as well. Of the six N. meningitidis
positives, we identified one serogroup A (Ghana), three
serogroup C (one from Togo and two from Nigeria), one
serogroup W (Niger), and one untyped likely due to low target
concentration (Nigeria).
Pathogen association with mortality. Among the 605
patients with outcome at discharge information, 9.8% died,
with the lowest rate in Ghana (2.4%) and the highest in Niger
andNigeria (16%each). Table 3 shows the pathogenmortality
rates. Detection of HIV and Plasmodium was associated with
the highest fatality rates of 50% and 29%, respectively.
DISCUSSION
Childhoodmeningitis poses amajor public health challenge
globally and is particularly problematic because it has diverse
infectious etiologies. This work shows the increased di-
agnostic yieldof usingapan-molecular syndromicTAC,which
revealed adiversity of 19 pathogens inCSF from five countries
in West Africa. Using the TAC assay increased the diagnostic
yield of meningitis to 20%, an approximate 10-fold increase
over bacterial culture or a triplex real-timePCRassay.25,26 The
sensitivity of TAC versus the earlier methods that were per-
formedwas very good, andmanymore detectionswere found
with TAC.
Several findings were notable. First, the TAC assay greatly
increased the detection of the pneumococcus versus the prior
triplex real-timePCR thatwasperformed. Both the triplex real-
time PCR assay and the TAC assay targeted the autolysin
encoding gene (lytA) of the S. pneumoniae. Therefore, the
improved pneumococcal detection with TAC was likely re-
lated to the greater volume of CSF tested and the DNA ex-
traction protocol. The pneumococcus is an extremely
important pathogen, was common across the age strata, and
the most common pathogen detected in CSF in Ghana and
Niger. Ghana had an earlier introduction of the 13-valent PCV
(PCV13) in 2012, achieving coverage of 90% by 2016. How-
ever, Ghana has experienced large outbreaks of pneumo-
coccal meningitis after PCV introduction.24 Implementation of
the TAC assay in routine surveillance would enhance the
monitoring of pneumococcal meningitis in the post-PCV era
across the subregion. To further enhance such surveillance, it
would be useful to examine serotypes using direct molecular
tools,33 and these can be incorporated into a future TAC ver-
sion. Worth noting is that TAC is easy to use and modular for
customized use,8 with a reagent cost of ∼$60/sample and 3-
hour running time from sample to results.
Over the last century, populations in Africa’smeningitis belt,
which includesSenegal, Togo,Niger, and the northern regions
of Ghana and Nigeria, have borne the brunt of meningococcal
meningitis outbreaks.34 SerogroupAmeningococcuswas the
dominant cause of meningitis outbreaks until the rollout of
MenAfriVac across countries in the meningitis belt between
2010 and 2018.5 However, the emergence of serogroup C,W,
and X strains with epidemic potential threaten the success of
MenAfriVac.35–38 Using the TAC assay, we confirmed one
serogroup W and three serogroup C meningitis cases. A
meningococcal serogroup A meningitis case was also de-
tected and warrants further investigation. Themeningococcal
capsular typing included in the TAC assay could be of great
value during outbreak emergencies because reactive vacci-
nation campaigns depend on rapid and accurate identification
of the meningococcal serogroup causing the outbreak.39
The TAC assay also highlighted the potential importance of
E. coli, particularly in Nigeria and Senegal. Escherichia coli is
TABLE 3
Pathogen association with mortality
Total Fatality rate before discharge (%)
CMV 4 25
Dengue 5 0
Escherichia coli 28 18
Enterovirus 3 0
HHV 6 3 33
HIV 4 50
Klebsiella pneumoniae 15 20
Neisseria meningitidis 5 0
Parvovirus B19 10 10
Plasmodium 17 29
Streptococcus agalactiae 7 14
Staphylococcus aureus 19 11
Streptococcus pneumoniae 23 17
No pathogen 414 8
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well known to be a common cause of neonatal meningitis.40
The high rate of Gram-negative pathogens such as E. coli and
K. pneumoniae, particularly in older age categories, was no-
table. Many of these specimens had highly meningitic CSF
indices; thus, we suspect these PCR diagnoses are accurate.
Although Gram-negative meningitis is less common in older
children, comorbidities such as malnutrition may have con-
tributed to this finding.41,42 Escherichia coli culture–positive
rates of 1–16% have been reported in other studies of
childhood meningitis in Nigeria and Ghana.43–45 The Gram-
negative bacteria causing meningitis is also concerning
because they are associated with the highest rates of anti-
microbial resistance.46
Staphylococcus aureus was also quite common, particu-
larly in the first month of life. This pathogen is often associated
with meningitis and sepsis in the neonatal period, particularly
in low birth weight infants (information we did not collect).47
However, S. aureus has been commonly reported as a cause
of meningitis by culture in recent reports from Nigeria.48
Beyond bacteria, there were a number of additional in-
teresting findings. There was substantial Plasmodium in the
CSF. We suspect these Plasmodium detections reflected
cerebral malaria, particularly given the high mortality. Indeed,
cerebral malaria has been noted to be a major etiology in
children with suspected meningitis,49 but it is usually di-
agnosed based on blood smear and clinical grounds. Notably,
Plasmodium was not detected in individuals with meningitic
CSF profiles, suggesting this was not meningitis per se. Al-
though the detection ofmalaria inCSF could simply bedue to
blood contamination of CSF, we think this is unlikely. In one
study, the detection of Plasmodium HRP-2 protein in CSF,
but not plasma, was associated with high mortality in cere-
bral malaria; thus, DNA detection in the CSF46 is quite
plausible.50 Parvovirus B19 was quite common in older
children and is well known to be able to cause meningitis.51
Group B Streptococcus meningitis was also detected and
found predominantly among neonates, which is consistent
with previous findings.14,52
This study has several limitations. First, this study used
sentinel-based disease surveillance. Specimens collected
through nationwide case-based surveillance systems for
meningitis would have been ideal; however, this type of sur-
veillance for meningitis is not operational in most of the West
African countries active in the PBM surveillance. The MenA-
friNet consortium which has supported the implementation of
case-based meningitis surveillance in Burkina Faso, Chad,
Mali, Niger, and northern Togo has demonstrated the utility of
such efforts.53 The representativeness of the findings is also
limited in that not all the CSF specimens were available for
testing; for instance, only 19% of specimens from Senegal
were available for TAC testing. There were also large differ-
ences in the age distributions of children presenting with
suspected meningitis across the various countries. This
means that any intercountry comparisons need to be inter-
preted with caution. Most of the suspected cases had white
blood cell counts less than 10cells/mm3 andglucose >40mg/
dL, which are not suggestive of probable meningitis. There
may be several explanations for this which include overlap of
the WHO meningitis case definition with other serious febrile
illness. This could certainly be the case for Togo, where the
dominant pathogen detected was Plasmodium. High rates of
antibiotic treatment before lumbar puncture (e.g., 71% in
Ghana) could also contribute to low white blood cell counts in
children meeting the case definition.9
We found that 4.4%of specimenshadcoinfections,with the
most common combinations including Plasmodium and a
bacterium or a virus (CMV or EBV). Although there is evidence
that viral and bacterial coinfections do occur in meningitis
patients and may be associated with higher mortality,54 these
findings warrant thorough investigation in future studies. The
significance of CMV also needs further investigation.55
In summary, this meningitis TAC provided an abundance of
useful information beyond culture and routine triplex PCR
assays to understand the etiologies of meningitis in West Af-
rican children. A cornerstone to defeatingmeningitis by 20307
will be to ascertain the various causes of meningitis and im-
plement the appropriate control and prevention strategies.
SEnhancedmeningitis case ascertainment could be achieved
through the implementation of better molecular detection in
meningitis surveillance programs.
Received July 30, 2019. Accepted for publication March 30, 2020.
Note: Supplemental files appear at www.ajtmh.org.
Acknowledgments: Meningitis surveillance is implemented by the
Ministries of Health (Senegal, Ghana, Togo, Nigeria, and Niger) with
support from the WHO through the Data Strategic Focus Area (SFA)
grant fromGavi, the Vaccine Alliance. TheMRCG at LSHTMhosts the
WHOCCNVSandalsoservesas theWHORRL for IBDwhichprovides
laboratory support to the surveillance activities. The TAC diagnostics
were supported by the National Institute of Allergy and Infectious
Diseases K24AI102972. We thank Barry Fields and Clayton Onyango
of CDC for their input on devising this card and their work on an earlier
version.
Financial support: This work was supported by the WHO Regional
Office for Africa. Gavi, the Vaccine Alliance, provided funding to the
WHO support new vaccines sentinel surveillance implemented by the
national governments and support for Regional Reference laboratory
at the Medical Research Council Unit,Tthe Gambia. The TAC diag-
nostics were supported by the National Institute of Allergy and In-
fectious Diseases K24AI102972.
Disclosure: The datasets supporting the conclusions of this article are
available on request. E. H. reports grants from National Institutes of
Health during the conduct of the study.
Disclaimer: The findings and conclusions in this report are those of the
author(s) and do not necessarily represent the official position of MRC
Unit, the Gambia, at LSHTM or the WHO.
Authors’ addresses: Brenda A. Kwambana-Adams, WHO Collabo-
rating Centre for New Vaccines Surveillance, Medical Research
Council Unit The Gambia at London School of Hygiene and Tropical
Medicine, Banjul, The Gambia, and NIHR Global Health Research
Unit onMucosal Pathogens, Division of Infection and Immunity, University
College London, London, United Kingdom, E-mail: brenda.kwambana@
ucl.ac.uk. Jie Liu, Jean Gratz, and Eric Houpt, Division of Infectious Dis-
eases and International Health, Department of Medicine, University of Vir-
ginia,Charlottesville,VA,E-mails: jl5yj@virginia.edu, jean.gratz@gmail.com,
and erh6k@hscmail.mcc.virginia.edu. Catherine Okoi, Nuredin I. Moham-
med, Archibald Worwui, Peter Ndow, and Martin Antonio, WHO Collabo-
rating Centre for New Vaccines Surveillance, Medical Research Council
Unit The Gambia at London School of Hygiene and Tropical Medicine,
Banjul, The Gambia, E-mails: cokoi@mrc.gm, nimohammed@mrc.gm,
warchibald@mrc.gm,psndow@mrc.gm,andmantonio@mrc.gm.JasonM.
Mwenda and RichardMihigo, World Health Organization (WHO), Regional
Office for Africa, Brazzaville, Congo, E-mails: mwendaj@who.int and
mihigor@who.int. Enyonam Tsolenyanu, Department of Paediatrics, Syl-
vanus Olympio Teaching Hospital, Lome´, Togo, E-mail: tsolenyanu_
enyonam@yahoo.fr. Lorna Awo Renner, Department of Child Health, Uni-
versity of Ghana School of Medicine and Dentistry, Accra, Ghana, E-mail:
lornarenner@gmail.com.DanielAnsong,KomfoAnokyeTeachingHospital,
Kumasi, Ghana, E-mail: ansongd@yahoo.com. Beckie N. Tagbo, Institute
of Child Health, University of Nigeria TeachingHospital, Enug, Nigeria, and
6 KWAMBANA-ADAMS AND OTHERS
Department of Paediatrics, University of Nigeria Teaching Hospital, Enug,
Nigeria, E-mail: tagbobeckie@yahoo.com. Muhammad F. Bashir, De-
partment of Paediatrics, Abubakar Tafawa Balewa University Teaching
Hospital, Bauchi, Nigeria, E-mail: mbashirfaruk@gmail.com. Mamadou
Kourna Hama, Laboratoire, Hopital National de Niamey, Niamey, Niger,
E-mail: hakom_kourna@yahoo.fr. Mouhamadou A. Sonko, Department of
Microbiology, Centre Hospitalier National d’Enfants Albert Royer, Dakar,
Senegal, E-mail: sonkoa160@gmail.com. Adam L. Cohen and Fatima
Serhan, World Health Organization, Vaccines and Biologicals, IVB/EPI,
Geneva, Switzerland, E-mails: cohena@who.int and serhanfa@who.int.
Martin Antonio,WHOCollaboratingCentre for NewVaccines Surveillance,
Medical Research Council Unit The Gambia at London School of Hygiene
and Tropical Medicine, Banjul, The Gambia, and Division of Microbiology
and Immunity, Warwick Medical School, University of Warwick, Coventry,
United Kingdom, E-mail: mantonio@mrc.gm.
This is an open-access article distributed under the terms of the
Creative Commons Attribution (CC-BY) License, which permits un-
restricted use, distribution, and reproduction in anymedium, provided
the original author and source are credited.
REFERENCES
1. Brandtzaeg P, van Deuren M, 2012. Classification and patho-
genesis of meningococcal infections. Methods Mol Biol 799:
21–35.
2. Collaborators GBDM, 2018. Global, regional, and national burden
of meningitis, 1990–2016: a systematic analysis for the Global
Burden of Disease Study 2016. Lancet Neurol 17: 1061–1082.
3. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moisi JC, Were F,
Levine OS, 2009. Sequelae due to bacterial meningitis among
African children: a systematic literature review.BMCMed7: 47.
4. Wahl B et al., 2018. Burden of Streptococcus pneumoniae and
Haemophilus influenzae type b disease in children in the era of
conjugate vaccines: global, regional, and national estimates
for 2000–15. Lancet Glob Health 6: e744–e757.
5. Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-
BenissanC, RonveauxO, Pre´ziosiMP, Stuart JM, 2017. Impact
of MenAfriVac in nine countries of the African meningitis belt,
2010–15: an analysis of surveillance data. Lancet Infect Dis
17: 867–872.
6. Mwenda JM et al., 2019. Pediatric bacterial meningitis surveil-
lance in the World Health Organization African region using the
invasive bacterial vaccine-preventable disease surveillance
network, 2011–2016. Clin Infect Dis 69 (Suppl 2): S49–S57.
7. WHO, ■. Defeating Meningitis by 2030: First Meeting of the Tech-
nical Taskforce. Available at: https://www.who.int/immunization/
research/Defeating_meningitis_2030_TTFJuly2018_report.pdf.
8. Liu J et al., 2014. Development and assessment of molecular di-
agnostic tests for 15 enteropathogens causing childhood di-
arrhoea: a multicentre study. Lancet Infect Dis 14: 716–724.
9. Sacchi CT et al.; RT-PCR Surveillance Project Team, 2011. In-
corporation of real-time PCR into routine public health sur-
veillance of culture negative bacterial meningitis in Sao Paulo,
Brazil. PLoS One 6: e20675.
10. HeinsbroekE, LadhaniS,GrayS,GuiverM,Kaczmarski E,Borrow
R, Ramsay M, 2013. Added value of PCR-testing for confir-
mation of invasive meningococcal disease in England. J Infect
67: 385–390.
11. MooreCC, JacobST, Banura P, Zhang J, Stroup S, BoulwareDR,
Michael Scheld W, Houpt ER, Liu J, 2019. Etiology of sepsis in
Uganda using a quantitative polymerase chain reaction-based
TaqMan array card. Clin Infect Dis 68: 266–272.
12. Abade A et al., 2018. Use of TaqMan array cards to screen out-
break specimens for causes of febrile illness in Tanzania. Am
J Trop Med Hyg 98: 1640–1642.
13. Velaphi SC et al., 2019. Surveillance for incidence and etiology of
early-onset neonatal sepsis in Soweto, South Africa.PLoSOne
14: e0214077.
14. Saha SK et al., 2018. Causes and incidence of community-
acquired serious infections among young children in southAsia
(ANISA): an observational cohort study. Lancet 392: 145–159.
15. Liu J et al., 2016. Use of quantitative molecular diagnostic
methods to identify causes of diarrhoea in children: a reanalysis
of the GEMS case-control study. Lancet 388: 1291–1301.
16. SonkoMA et al., 2019. Changes in themolecular epidemiology of
pediatric bacterial meningitis in Senegal after pneumococcal
conjugate vaccine introduction. Clin Infect Dis 69 (Suppl 2):
S156–S63.
17. Renner LA et al., 2019. Hospital-based surveillance for pediatric
bacterial meningitis in the era of the 13-valent pneumococcal
conjugate vaccine in Ghana. Clin Infect Dis 69 (Suppl 2):
S89–S96.
18. Tsolenyanu E et al., 2019. Etiology of pediatric bacterial menin-
gitis pre- and post-PCV13 introduction among children under 5
years old in lome´, Togo.Clin Infect Dis 69 (Suppl 2): S97–S104.
19. Tagbo BN et al., 2019. Pediatric bacterial meningitis surveillance
in Nigeria from 2010 to 2016, prior to and during the phased
introductionof the10-valentpneumococcal conjugatevaccine.
Clin Infect Dis 69 (Suppl 2): S81–S8.
20. Kourna Hama M et al., 2019. Pediatric bacterial meningitis surveil-
lance in Niger: increased importance of Neisseria meningitidis
serogroup C, and a decrease in Streptococcus pneumoniae fol-
lowing 13-valent pneumococcal conjugate vaccine introduction.
Clin Infect Dis 69 (Suppl 2): S133–S139.
21. Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S, 2009.
Epidemic meningitis due to group A Neisseria meningitidis in
the African meningitis belt: a persistent problem with an immi-
nent solution. Vaccine 27 (Suppl 2): B13–B19.
22. World Health Organization, 2018. WHO position paper, menin-
gococcal a conjugate vaccine: updated guidance, February
2015. Vaccine 36: 3421–3422.
23. WHO, 2014. Meningitis Outbreak Response in Sub-Saharan
Africa: WHO Guideline. Geneva, Switzerland: World Health
Organization.
24. Kwambana-AdamsBAet al., 2016.Anoutbreakof pneumococcal
meningitis among older children (³5 years) and adults after the
implementation of an infant vaccination programme with the
13-valent pneumococcal conjugate vaccine in Ghana. BMC
Infect Dis 16: 575.
25. Vuong J et al., 2016. Development of real-time PCR methods for
the detection of bacterial meningitis pathogens without DNA
extraction. PLoS One 11: e0147765.
26. Wang X 2011. Detection of bacterial pathogens in Mongolia
meningitis surveillance with a new real-time PCR assay to de-
tectHaemophilus influenzae. Int JMedMicrobiol 301:303–309.
27. Collaborators GM, 2017. Global, regional, and national under-5
mortality, adult mortality, age-specific mortality, and life ex-
pectancy, 1970–2016: a systematic analysis for the Global
Burden of Disease Study 2016. Lancet 390: 1084–1150.
28. Onyango CO et al., 2017. Evaluation of a TaqMan array card for
detection of central nervous system infections. J ClinMicrobiol
55: 2035–2044.
29. DiazMH et al., 2013. Optimization of multiple pathogen detection
using the TaqMan array card: application for a population-
based study of neonatal infection. PLoS One 8: e66183.
30. Liu J et al., 2016. Optimization of quantitative PCR methods for
enteropathogen detection. PLoS One 11: e0158199.
31. Liu J et al., 2016. Development of a TaqMan array card for acute-
febrile-illness outbreak investigation and surveillance of
emerging pathogens, including ebola virus. J Clin Microbiol
54: 49–58.
32. Centers for Disease Control and Prevention (CDC), 2009. Pediatric
bacterial meningitis surveillance–African region, 2002–2008.
MMWRMorb Mortal Wkly Rep 58: 493–497.
33. Pholwat S, Sakai F, Turner P, Vidal JE, Houpt ER, 2016. Devel-
opment of a TaqMan array card for pneumococcal serotyping
on isolates and nasopharyngeal samples. J Clin Microbiol
54: 1842–1850.
34. GreenwoodB, 2006. Editorial: 100 years of epidemicmeningitis in
West Africa–has anything changed? Trop Med Int Health 11:
773–780.
35. Kwambana-Adams BA et al., 2018. Meningococcus serogroup C
clonal complex ST-10217 outbreak in Zamfara state, northern
Nigeria. Sci Rep 8: 14194.
36. Sidikou F et al., 2016. Emergence of epidemic Neisseria menin-
gitidis serogroup C in Niger, 2015: an analysis of national sur-
veillance data. Lancet Infect Diseases 16: 1288–1294.
37. Retchless AC et al., 2018. Molecular characterization of invasive
meningococcal isolates in Burkina Faso as the relative
ETIOLOGY OF PEDIATRIC MENINGITIS IN WEST AFRICA 7
importance of serogroups X and W increases, 2008–2012.
BMC Infect Dis 18: 337.
38. BrynildsrudOB, EldholmV, Bohlin J, UadialeK,ObaroS, Caugant
DA, 2018. Acquisition of virulencegenes by a carrier strain gave
rise to the ongoing epidemics of meningococcal disease in
West Africa. Proc Natl Acad Sci USA 115: 5510–5515.
39. WHO, 2015. Preparedness for outbreaks of meningococcal
meningitis due to Neisseria meningitidis serogroup C in Africa:
recommendations from a WHO expert consultation.Wkly Epi-
demiol Rec 90: 633–636.
40. Furyk JS, Swann O, Molyneux E, 2011. Systematic review: neo-
natal meningitis in the developing world. Trop Med Int Health
16: 672–679.
41. Roine I,WeisstaubG, PeltolaH; LatAmBacterialMeningitis Study
Group, 2010. Influence of malnutrition on the course of child-
hood bacterial meningitis. Pediatr Infect Dis J 29: 122–125.
42. Mulla MI, Moosajee I, Rubidge CJ, Moosa A, 1984. Nutritional
status of children with pyogenic meningitis. J Trop Pediatr 30:
303–306.
43. Kuti BP, Bello EO, Jegede TO, Olubosede O, 2015. Epidemio-
logical, clinical and prognostic profile of childhood acute bac-
terial meningitis in a resource poor setting. J Neurosci Rural
Pract 6: 549–557.
44. Nwadioha SI, Nwokedi EO, Onwuezube I, Egesie JO, Kashibu E,
2013.Bacterial isolates fromcerebrospinal fluid of childrenwith
suspected acutemeningitis in a Nigerian tertiary hospital.Niger
Postgrad Med J 20: 9–13.
45. OwusuM, Nguah SB, Boaitey YA, Badu-Boateng E, Abubakr AR,
Lartey RA, Adu-Sarkodie Y, 2012. Aetiological agents of cere-
brospinal meningitis: a retrospective study from a teaching
hospital in Ghana. Ann Clin Microbiol Antimicrob 11: 28.
46. Li G et al., 2020. Towards understanding global patterns of anti-
microbial use and resistance in neonatal sepsis: insights from
the NeoAMR network. Arch Dis Child 105: 26–31.
47. Medugu N, Iregbu K, Iroh Tam PY, Obaro S, 2018. Aetiology of
neonatal sepsis in Nigeria, and relevance of Group b strepto-
coccus: a systematic review. PLoS One 13: e0200350.
48. Airede KI, Adeyemi O, Ibrahim T, 2008. Neonatal bacterial men-
ingitis and dexamethasone adjunctive usage in Nigeria.Niger J
Clin Pract 11: 235–245.
49. Page AL et al., 2017. Aetiology and outcomes of suspected in-
fections of the central nervous system in children in Mbarara,
Uganda. Sci Rep 7: 2728.
50. Thakur KT, Vareta J, Carson KA, Kampondeni S, Potchen MJ,
Birbeck GL, MacCormick I, Taylor T, Sullivan DJ, Seydel KB,
2018. Cerebrospinal fluidPlasmodium falciparum histidine-rich
protein-2 in pediatric cerebral malaria.Malar J 17: 125.
51. Barah F, Vallely PJ, Chiswick ML, Cleator GM, Kerr JR, 2001.
Association of human parvovirus B19 infection with acute
meningoencephalitis. Lancet 358: 729–730.
52. OkomoU, Akpalu ENK, Le Doare K, Roca A, Cousens S, Jarde A,
Sharland M, Kampmann B, Lawn JE, 2019. Aetiology of
invasive bacterial infection and antimicrobial resistance in
neonates in sub-Saharan Africa: a systematic review andmeta-
analysis in line with the STROBE-NI reporting guidelines. Lan-
cet Infect Dis 19: 1219–1234.
53. Patel JC et al., 2019. MenAfriNet: a network supporting case-
based meningitis surveillance and vaccine evaluation in the
meningitis belt of Africa. J Infect Dis 220 (Suppl 4): S148–S154.
54. Kelly MJ et al., 2012. Epstein-barr virus coinfection in cerebro-
spinal fluid is associated with increased mortality in Malawian
adults with bacterial meningitis. J Infect Dis 205: 106–110.
55. Leber AL et al., 2016. Multicenter evaluation of BioFire FilmArray
meningitis/encephalitis panel for detection of bacteria, viruses,
and yeast in cerebrospinal fluid specimens. J ClinMicrobiol 54:
2251–2261.
8 KWAMBANA-ADAMS AND OTHERS
Supplemental File 1: Year of introduction of the Hib conjugate vaccine, PCV 
and MenAfriVac 
 
 
 
 
 
 
 
 
 
Data sources 
1. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/
tswucoveragedtp1.html 
 
2. https://www.path.org/vaccines/  
 
 
3. https://www.afro.who.int/sites/default/files/2017-06/oms-ivb-rvap-afro-en-
20150408_final_sent140317_0.pdf?ua=1 
 
 
Country Hib PCV MenAfriVac 
Ghana 2002 2012 2012 
Niger 2008 2014 2010 
Nigeria 2012 2014 2011 
Senegal 2005 2013 2012 
Togo 2008 2014 2014 
Supplemental File 2. Table of qPCR assays validated on the TaqMan Array Card in this study 
Pathogen Gene Forward Reverse  MGB probe Reference 
HIV I LTR GCCTCAATAAAGCTTGCCTTGA GGGCGCCACTGCTAGAGA CCAGAGTCACACAACAGACGGGCACA 1 
HIV II Protease CACCACACAGAGAGGCGACAGAGGA TGACCCTCGATATATGCTTGGACTACTGGTC TGCTGCACCTCAATTCTCTCTTTGG 1 
  CACCATGCAGGGARACGACAGAGGA TGACCCTCRATGTRTGCTGTGACTACTGGTC   
  GACCCTACAAGGAGGTGACRGAGGA TGACCCTCRATACATGCTTTGACTACTGGTC   
Parvovirus B19 VP2 AAGCCGTGTGCACCCATT GTACTGGTGGGCGTTTAGTTACG TAAACACTCCCCACCGTGC 2, modified 
H. influenzae B bcs3 CAAGATACCTTTGGTCGTCTGCTA TAGGCTCGAAGAATGAGAAGTTTTG ATGATATGGGTACATCTGTT 3 
N. meningitidis A sacB AAAATTCAATGGGTATATCACGAAGA ATATGGTGCAAGCTGGTTTCAATAG CAAAGTGCCCTTCCTAC 4, modified 
N. meningitidis B synD GCTACCCCATTTCAGATGATTTGT ACCAGCCGAGGGTTTATTTCTAC  CATAGTTGTTRCCCATCTCT 4, modified 
N. meningitidis C synE CCCTGAGTATGCGAAAAAAATT TGCTAATCCCGCCTGAATG TTTCAATGCTAATGAATACCACCG 4, modified 
N. meningitidis W synG TATTTATGGAAGGCATGGTGTATG TTGCCATTCCAGAAATATCACC CTGTAATCATTCGCTCCATA 4, modified 
N. meningitidis X xcbB TGTCCCCAACCGTTTATTGG TGCTGCTATCATAGCCGCC TGTTTGCCCACATGAATGGC 4, modified 
N. meningitidis Y synF TCCGAGCAGGAAATTTATGAGAATAC TTGCTAAAATCATTCGCTCCATAT TATGGTGTACGATATCCCTATC 4, modified 
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Supplemental File 3. Comparison of detection methods for N. meningitidis, S. pneumoniae and H. influenzae 
 
 H.influenzae 
TAC + 
H.influenzae 
TAC - 
N. 
meningitidis 
TAC + 
N. 
meningitidis 
TAC - 
S. 
pneumoniae 
TAC + 
S. 
pneumoniae 
TAC - 
Culture + 1 0 1 1 3 0 
- 0 701 4 696 22 677 
Triplex 
PCR 
+ 0 1 3 0 4 1 
- 0 461 2 457 17 440 
 
